Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma

Melanoma Research

Volumn 16, Issue 4, 2006, Pages 317-323

  Guida, Michele ^a   Riccobon, Angela ^b   Biasco, Guido ^c   Ravaioli, Alessandra ^d   Casamassima, Addolorata ^a   Freschi, Andrea ^e   Palma, Maurizio Dalla ^f   Galligioni, Enzo ^g   Nortilli, Rolando ^h   Chiarion Sileni, Vanna ⁱ   Picozzo, Jacopo ⁱ   Romanini, Antonella ^j   Nanni, Oriana ^d   Ridolfi, Ruggero ^b  

^a Istituto Oncologico   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f SAN BORTOLO HOSPITAL   (Italy)

^g SANTA CHIARA HOSPITAL   (Italy)

^h Maggiore Hospital   (Italy)

ⁱ Department of Medical Oncology   (Italy)

^j UNIVERSITY OF PISA   (Italy)

more..

Author keywords

Bio chemotherapy; Cytokines; Metastatic melanoma

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CISPLATIN; CYTOKINE; DACARBAZINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SKIN METASTASIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; CISPLATIN; CYTOKINES; DACARBAZINE; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MELANOMA; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; SKIN NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; VINBLASTINE;

EID: 33746220285     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000200491.00841.5f     Document Type: Article

References (43)

1. Ridolfi R, Chiarion-Sileni V, Guida M, Romanici A, Labianca R, Freschi A, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: results from an italian multicenter phase iii randomized clinical trial. J Clin Oncol 2002; 20:1600-1607.
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
3. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16:2921-2929.
4. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19:3477-3482.
5. Guida M, Ravaioli A, Sileni VC, Romanici A, Labianca R, Freschi A, et al. Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (Italian melanoma inter-group) trial. J Transl Med 2003; 22:13
6. Sen GC. The interferons. In: Remick DG, Friedland JS, editors. Cytokines in health and disease. 2nd ed. New York: Marcel Dekker, Inc.; 1997. pp. 199-208.
7. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96:3302-3309.
8. Kishimoto T, Terada T, Yamagami S, Sugimura T, Nishio S, Makawa M. Correlation between blood prostaglandins, plasma lipids and atherosclerosis in dialyzed patients. Blood Purif 1990; 8:141-148.
9. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin. Immunol Today 1990; 11:443-449.
10. Lu C, Kerber RS. Interleukin 6: transition from paracrine growth inhibitor to intracellular autocrine stimulator during human melanoma progression. J Cell Biol 1993; 120:1281-1288.
11. Tamm I, Cardinale I, Krueger J, Murphy JS, May LT, Sehgal PB. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J Exp Med 1989; 170:1649-1669.
12. Zhou D, Munster A, Winchurch RA. Pathologic concentrations of interleukin 6 inhibit T cell responses via induction of activation of TGF-β. FASEB J 1991; 5:2582-2585.
13. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta2/B-cell stimulating factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the acute phase response in liver cells. Proc Natl Acad Sci USA 1987; 84:7251-7259.
14. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinric PC. Acute phase response of human hepatocytes: regulation of acute phase protein synthesis by IL-6. Hepatology 1990; 12:1179-1186.
15. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15:74-80.
16. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diaminedichloro platinum and etoposide-mediate cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995; 55:4633-4639.
17. Moretti S, Chiarugi A, Semplici F, Salvi A, De Giorgi V, Fabbri P, et al. Serum imbalance of cytokines in melanoma patients. Melanoma Res 2001; 11:395-399.
18. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of IL-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992; 52:3317-3322.
19. Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: A French Multiinstitutional Study. J Clin Oncol 1996; 14:1697-1703.
20. Gastl AG, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993; 55:96-101.
21. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-924.
22. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995; 5:67-68.
23. Mule' JJ, McIntosh JK, Jablons DM, Rosenberg SA. Antitumor activity of recombinant interleukin 6 in mice. J Exp Med 1990; 171:623-636.
24. Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT. Systemic administration of cellular IL-10 induces an effective, specific and long-lived immune response against established tumors in mice. J Immunol 1996; 157:231-238.
25. Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, et al. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer 1999; 84:160-168.
26. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78:1198-1204.
27. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, et al. Serum interleukin-6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994; 63: 911-913.
28. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R. The relationship between weight loss and interleukin-6 in non-small cell lung cancer. Br J Cancer 1996; 73:1560-1562.
29. Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, Paradiso A, et al. C-reactive protein: a biomarker of survival in metastatic renal cell carcinoma patients treated with subcutaneous interleukin-2-based immunotherapy. J Urol 2005; 173:52-55.
30. Walther MM, Johnson B, Culley D, Shah R, Weber J, Venzon D, et al. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol 1998; 159:718-722.
31. Wang JM, Taraboletti G, Matsushima K, Van Damme J, Mantovani A. Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem Biophys Res Commun 1990; 169:165-170.
32. Gimbrone MA Jr, Obin MS, Brock AF, Luis EA, Hass PE, Hebert CA, et al. Endothelial interleukin-8: a novel inhibitor of leukocite-endothelial interactions. Science 1989; 246:1601-1603.
33. Scheibenbogen C, Mohler T, Haefele J, Hunstein W, Keilhoz U. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumor load. Melanoma Res 1995; 5:179-181.
34. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994; 153:1696-1706.
35. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol 1996; 106:1114-1118.
36. Rubin LA, Jay G, Nelson DL. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol 1986; 137:3841-3844.
37. Urba WJ, Hartmann LC, Longo DL, Steis RG, Smith JW 2nd, Kedar I, et al. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. Cancer Res 1990; 50:2979-2986.
38. Fierro MT, Lisa F, Novelli M, Bertero M, Bernengo MG. Soluble interleukin-2 receptor, CD4 and CD8 levels in melanoma: a longitudinal study. Dermatology 1992; 184:182-189.
39. Hanninen EL, Korfer A, Hadam M, Schneekloth C, Dallmann I, Menzel T, et al. Biological monitoring of low-dose interleukin-2 in humans: soluble interleukin 2 receptors, cytokines and cell phenotypes. Cancer Res 1991; 51(23 Pt 1):6312-6316.
40. Lissoni P, Tisi E, Brivio F, Barni S, Rovelli F, Perego M, et al. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. Eur J Cancer 1991; 27:1014-1015.
41. Soubrane C, Mouawad R, Ichen M, Suissa J, Borel C, Vuillemin E, et al. Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. Clin Exp Immunol 1994; 95:232-236.
42. Guida M, Abbate I, Casamassima A, Musci MD, Latorre A, Lorusso V, et al. Long-term subcutaneous recombinant interleukin-2 as maintainance therapy: biological effects and clinical implications. Cancer Biother 1995; 10:195-203.
43. Lissoni P, Mengo S, Mandala M, Mauri E, Brivio F, Rovelli F, et al. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy. J Biol Regul Homeost Agents 1998; 12:38-41.